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pen access Abstract Objectives: Postspinal shivering is a frequent complication following spinal anesthesia.
The aim of this study was to compare the effectiveness of nefopam with that of ketamine plus
midazolam and placebo in the prevention of postspinal shivering.
Methods: We studied 226 patients undergoing elective orthopedic surgery. Patients were located to
one of three groups, group N (n= 76) received 0.2 mg kg1 nefopam, group K (n= 75) received
ketamine 0.25 mg plus midazolam 40 lg kg1 and group S (n= 75) received saline 0.9% as
placebo.
Results: We found a signiﬁcant reduction in the incidence of shivering in group N and group K in
comparison to group S. There were no signiﬁcant differences in hypotenion and bradycardia in all
groups. Sedation was signiﬁcant in group K in comparison with group N and S.
Conclusion: The results of our study showed that nefopam (0.2 mg kg1) is as effective as ketamine
0.25 mg plus midazolam 40 lg kg1 in the prophylaxis of postspinal shivering and not accompanied
by sedation or hemodynamic side effects.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.830981.
(N.S. Hussein).
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Shivering frequently follows regional anesthesia. It is consid-
ered as one of the most common complications of anesthesia.
Shivering is deﬁned as an involuntary movement of one or
more muscle occurring during the early phase following regio-
nal or general anesthesia [1].
Postspinal shivering may lead to patient discomfort and can
cause more severe complications in patients with history of
cardio-respiratory diseases. These complications include in-
creased oxygen consumption, hypoxemia, increased carbon
dioxide production and lactic acidosis [2], also, during shiver-
ing patients’ intracerebral and intraocular pressure increase, in
addition, interference with the monitoring of ECG and blood
pressure may occur [3–5].
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methods to prevent and treat shivering, which recommended
certain drugs to be used for the control of shivering, such as
meperidine, ketamine plus midazolam, neostigmine and ketan-
serin [6,7].
Ketamine which is a competitive receptor antagonist of N-
methyl-D-aspartic acid (NMDA) has a role in thermoregula-
tion by different means [9]. NMDA receptor acts by modulat-
ing the noradrenergic and serotoninergic neurons in the locus
ceroleus. Also, NMDA receptors modulate ascending nocicep-
tive transmission at the dorsal horn of the spinal cord [10].
Ketamine controls shivering by non-shivering thermogenesis
either by the action on the hypothalamus or by the B-adrener-
gic effect of Norepinephrine [11].
Benzodiazepines have been found to reduce repetitive ﬁring
in response to depolarizing pulses in mouse spinal cord neurons
[12]. This functionmay be responsible for suppressing shivering.
Among benzodiazepines, diazepam has been found to be effec-
tive in the prevention of postspinal shivering [13]. It produces
minimal impairment of thermoregulatory control [14].
Nefopam hydrochloride is a non-sedative benzoxazocine
analgesic compound (3,4,5,6-tetrahydro-5-methyl-l-phenyl-
1H-2.5-benoxazocine hydrochloride), which prevents the syn-
aptic reuptake of dopamine, nor epinephrine and serotonin
in an amphetamine like fashion [8]. It is a non-opioid analgesic
drug that is safe and effective in preventing shivering after gen-
eral and neuraxial anesthesia with little effect on the sweating
and vasoconstriction thresholds [15–18].
In this study we shall compare the anti-shivering effect of
nefopam with that of ketamine plus midazolam in comparison
with placebo after spinal anesthesia, in addition to evaluating
any side effect of such medications.2. Methods
Following approval of the local ethical committee and written
informed consents, we studied 226 patients (ASA physical sta-
tus, I, II or III) scheduled to undergo knee arthroscopy (diag-
nostic and therapeutic), reduction and ﬁxation of tibia and
ﬁbula fractures. The surgeries were done in Demerdash Surgi-
cal Hospital (orthopedic unit). Patients were randomly allo-
cated to one of three groups:
Group N: received 0.2 mg kg1 nefopam (n= 76).
Group K: received 0.25 mg ketamine plus 40 lg kg1
midazolam (n= 75).
Group S: received same volume of saline 0.9% as placebo
(n= 75).
Participants were allocated to the study group by a com-
puter-generated random number assignment before the study
started using sealed envelopes that were opened just before
the patients entered the study. The studied drugs were diluted
with normal saline 0.9% in 20 ml ﬁxed volume and adminis-
tered intravenously 5 min before spinal anesthesia using a dou-
ble blind protocol. All the studied drugs were given to the
patients by staff anesthesiologist, blind to the study hypothesis.
The following patients were excluded from the study:
Those with a known allergy to any study medication, pa-
tients with a fever (temperature > 37.5 C), those with known
muscle diseases, Parkinson’s disease, impaired hepatic or renaldisease, patients taking MAOI or tricyclic antidepressants,
those who take alpha 2 agonist or beta receptor blockers as
medication, those with cardiac arrhythmias or heart failure
(NYHA III or IV), those with urinary retention, glaucoma
or known alcohol abuse.
All patients fasted for at least 6–8 h pre-operatively and just
before the spinal anesthesia were pre-hydrated with lactated
Ringer’s solution (15 ml kg1).
Standard monitoring including continuous electrocardio-
gram and heart rate, pulse oximetry, non-invasive automated
blood pressure measurement were recorded by anesthesia res-
ident blind to the patient group.
After complete aseptic technique, spinal anesthesia was in-
duced in all cases in the lateral decubitus position. Lumbar
puncture was done at L 3–4, with a 22 gauge Quincke spinal
needle via a midline approach after local inﬁltration of the area
with alkalinized 1% lidocaine (0.5 ml NaHCO3 for each 10 ml
lidocaine).
The cerebrospinal ﬂuid was aspirated, and 3 ml of heavy
bupivacaine (heavy marcaine, AstraZeneca) with 25 lg fenta-
nyl was injected through a spinal needle over a period of 15 s.
The spinal needle was withdrawn and the patients were reposi-
tioned supine with slight elevation of the head (15–20) for
comfort. Patients wore a cotton gown and were draped with
a single blanket. During the intra-operative period, all patients
were completely covered in surgical drapes except for the head
and neck area. No means of active warming were used. Ambi-
ent temperature of the operating rooms was maintained at 22–
25 C with constant humidity (a room humidity of approxi-
mately 55–65%). The sensory level was tested by pinprick sen-
sation and the maximum level of sensory block was the highest
level of disappearance of pinprick sensation reached during the
study period. Systolic arterial pressure (SAP), heart rate (HR),
peripheral oxygen saturation (SpO2), and sedation score
(0 = alert, 1 = awake but drowsy, 2 = asleep but arousable,
3 = unarousable) were measured. All measurements were re-
corded at baseline and then at 5, 10, 15, 20, 25, 30, 40, 50,
60, and 90 min after spinal anesthesia. Ephedrine 5–10 mg
i.v. was administered if SAP decreased less than 90 mm Hg
and may be repeated if needed. HR under 50 beats/min was
treated with atropine 0.5 mg i.v. Tympanic temperature was
monitored every 20 min using an ear thermometer (Insta-
Temp 9000; Welch Allyn, San Diego, CA). A tourniquet was
placed on the thigh to minimize blood loss. Fluid resuscitation
was given as follows as maintenance: ﬁrst 10 kgﬁ 4 ml/kg/H,
second 10 kgﬁ 2 ml/kg/H, then remaining body
weightﬁ 1 ml/kg/H of lactated ringer solution. As fasting:
maintenance volume X fasting hours. 50% in the ﬁrst hour
and 50% in the second hour.
The severity of post anesthetic shivering was assessed
according to a 5 point scale similar to that used by Wrench
et al. [19]: 0 = no shivering; 1 = one or more of the following
symptoms, piloerection, peripheral vasoconstriction, periphe-
ral cyanosis without other cause, but without visible muscular
activity; 2 = visible muscular activity conﬁned to one muscle
group; 3 = visible muscular activity in more than one muscle
group; 4 = gross muscular activity including the entire body.
The evaluation of patients’ shivering score was carried out
by an independent anesthetist unaware of patients’ grouping.
Patients in all groups were given intravenous dose of
meperidine (10–25 mg) if the drug under investigation failed
to prevent shivering.
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anesthesia care unit (PACU) with continuous monitoring of
blood pressure, heart rate and oxygen saturation.
The number of patients required in each group was calcu-
lated using a power calculation based on data obtained from
a previous clinical study on the incidence of post anesthetic
shivering following orthopedic surgery. These data suggest
that we could expect an incidence of shivering in the placebo
group of at least 40% and a reduction in the incidence to about
15% with an effective anti-shivering medication. So this study
was powered to detect a reduction in the incidence from 40%
to 15% with a error equal 0.05. With this assumption 71 pa-
tients per group were required. That is why we included 80 pa-
tients in each of the three groups.
Demographic data, duration of surgery, anesthesia and
time spent in PACU were analyzed using Student’s test, the
incidence of shivering and sedation was analyzed using Fish-
er’s exact test or v2-test. The ranked sum test of Raatz [20]
was used to analyze the severity of shivering (shivering score).
All values are expressed as mean (SD) or as median (range). A
p-values of <0.05 was considered signiﬁcant.
3. Results
240 patients were included in this study, 14 patients were ex-
cluded either due to refusal of the patient for regional anesthe-
sia or failure of anesthesia due to patient factor or
medications. So, 226 patients were included in the study.
All groups were similar with respect to demographic data,
duration of surgery and anesthesia and baseline tympanic tem-
peratures (Table 1).
The time to highest sensory level and maximal number of
segments blocked showed no differences among the groups.
Complete motor blockade of the lower extremities was ob-
served in all patients.
In patients treated with nefopam 0.2 mg kgl, 65 of 76 pa-
tients (85.5%) had no symptoms of shivering but 11 patients
(14.5%) showed signs of piloerection peripheral vasoconstric-
tion (shivering score grade 1). No patient in this group showed
any muscular activity (shivering score grade 2–4). In the keta-Table 1 Demographic characteristics, perioperative data and lowes
Nefopam 0.2 mg kg1
ASA grade
I 31 (40%)
II 38 (51%)
III 7 (9%)
Age (years) 53 ± 17
Sex: m/f 42:34
Weight (kg) 69 ± 17
Height (cm) 164 ± 11
Duration of surgery (min) 91 ± 43
Duration of anesthesia (min) 132 ± 53
Baseline tympanic temperature (C) 36.2 ± 0.5
Highest segment blocked (dermatome) T6
Time to reach highest block (min) 14.9 ± 5.2
Lowest HR (beats/min) 60.8 ± 11.2
Lowest SAP (mm Hg) 110.5 ± 14.2
Time in PACU (min) 92 ± 21
Data are presented as mean ± SD or median (range).mine plus midazolam treated patients, 63 of 75 were symptom
free (84%). 10 patients showed signs of piloerection, peripheral
vasoconstriction (13%), two patients reached shivering score
grade 2 (3%) and no patient reached score 3 or score 4. In
the placebo group 44 of 75 patients (59%) had no symptoms
of shivering but 31 patients (41%) showed signs of shivering.
Nine patients showed piloerection, peripheral vasoconstriction
(shivering score grade 1). 13 patients scored 2 & 3 and 9 scored
4 (Fig. 1).
By analyzing the shivering score, we found a signiﬁcant
higher grading in the placebo group compared to all other
groups (P< 0.01). The consumption of meperidine was signif-
icantly lower in the N and K groups compared to group S
(Table 2).
The patients in group K were more sedated than the other
two groups (Fig. 2). SAP and HR decreased signiﬁcantly after
spinal anesthesia in all groups, and the lowest SAP and HR
showed approximately 13–18% reduction compared with base-
line values, showing no differences among the three groups
(Table 1). SAP decreased to less than 90 mm Hg in seven pa-
tients in group K, six patients in group N and seven patients
in group S, respectively. Three patients in group K, four pa-
tients in group N and four patients in group S had HR be-
tween 43 and 45 beats/min. Oxygen saturation exceeded 94%
in all patients.
4. Discussion
Shivering associated with spinal and epidural anesthesia is a
common and uncomfortable side effect. It develops in up to
60% of patients. Redistribution of heat from core to periph-
ery, loss of thermoregulatory vasoconstriction below the level
of blockade resulting in an increased heat loss from body sur-
faces [21,22], and altered thermoregulation characterized by a
decrease in vasoconstriction threshold [23] are considered to be
the possible contributing factors to shivering.
Shivering causes patient distress and also lead to other ad-
verse effects, including increased oxygen consumption, lactic
acidosis, raised carbon dioxide production and increased left
ventricular systolic work index [24,25]. Prevention seemst vital signs.
Ketamine 0.25 mg plus midazolam 40 lg kg1 Placebo
35 (46%) 4 (45%)
36 (48%) 36 (48%)
4 (6%) 5 (7%)
50 ± 18 52 ± 16
39:36 41:34
72 ± 15 75 ± 12
167 ± 10 170 ± 9
93 ± 46 87 ± 45
141 ± 40 135 ± 52
36.1 ± 0.6 36.5 ± 0.6
T4 T5
15.2 ± 6.0 17.1 ± 10.1
62.3 ± 12.3 60.5 ± 12.5
106.2 ± 13.6 109.5 ± 16.6
93 ± 26 91 ± 30
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Figure 1 The number of patient in each group who suffered
from each degree of shivering *P< 0.05 compared with other
groups. 0 = no shivering; 1 = one or more of the following
symptoms, piloerection, peripheral vasoconstriction, peripheral
cyanosis without other cause, but without visible muscular
activity; 2 = visible muscular activity conﬁned to one muscle
group; 3 = visible muscular activity in more than one muscle
group; 4 = gross muscular activity including the entire body.
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Figure 2 The degree of sedation in all three groups. Data are
presented as number of patients. Sedation score: 0 = alert;
1 = awake but drowsy; 2 = asleep but arousable; 3 = unarous-
able. *P< 0.05 compared with other groups.
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tive, simple, in noxious and inexpensive.
In this study we compared the efﬁcacy of nefopam to keta-
mine plus midazolam and placebo for the prevention of shiver-
ing. The major ﬁnding was that nefopam 0.2 mg kg1
signiﬁcantly reduced the incidence of shivering as ketamine
plus midazolam compared to placebo.
Nefopam is a non-narcotic analgesic that shares no proper-
ties with the nonsteroidal anti-inﬂammatory agents and, in
contrast with narcotic analgesics, signiﬁcant opiate receptor
binding does not occur [26,27]. The relation between shivering
and the effects of drugs on vasoconstriction means that it is
possible to interpret our ﬁnding. The efﬁcacy of the drug in
the prevention of shivering is through its effect on patient shiv-
ering threshold and on the vasoconstriction threshold [28]. In
our study the tympanic temperature was not signiﬁcantly dif-
ferent between all groups at any time. Alfonsi et al. [29] has
demonstrated that nefopam causes a small increase in the core
temperature by decreasing the shivering threshold and not by
modifying sweating and vasoconstriction threshold so they
concluded that nefopam possesses a speciﬁc anti-shivering
effect.
A gold standard for the treatment and prevention of shiver-
ing has not been deﬁned [25]. However, ketamine increases
arterial pressure, heart rate and cardiac output because of di-Table 2 Perioperative consumption of meperidine.
Meperidine Nefopam
No. of patients (who received, %) 0 (0%)*
Consumption/patient (mg) 0
All values are expressed as median (range).
PACU= Post anesthesia recovery unit.
* P< 0.01 vs. placebo.rect sympathetic stimulation so it may be logical to use keta-
mine in patients who are at risk of hypothermia [30].
Sagir and colleagues [31] showed that ketamine 0.5 mg kg1
intravenously prevents postspinal shivering but patients may
develop postoperative hallucinations and nausea or vomiting.
In our study, we used midazolam + ketamine so patients
didn’t suffer from hallucinations postoperatively. Goold and
Colleagues [32] studied patients undergoing brachytherapy
for cancer cervix and found that midazolam administration to-
wards the end of anesthesia hasten the gain of core tempera-
ture and prevent shivering postoperatively and this is similar
to the results in this study.
Kurz and colleagues [14] found that the reduction in heat
production after administration of midazolam is less than that
after induction of anesthesia with clinical doses of volatile
anesthetics, propofol and opioids.
Kinoshita and colleagues [33] showed that infusion of a low
dose ketamine prevents decrease in body temperature of pa-
tients during spinal anesthesia which is similar to the results
of the present study.
Honarmand and Safayi [9] found that the prophylactic use
of ketamine + midazolam i.v. was more effective than keta-
mine i.v. or midazolam i.v. in preventing postspinal shivering.
5. Conclusion
From this study we conclude that nefopam 0.2 mg kg1 signif-
icantly decreases the incidence of postspinal shivering as keta-Ketamine plus midazolam Placebo
2 (3%)* 22 (29%)
10–20 20–50
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placebo. The better prophylactic anti-shivering efﬁcacy of nef-
opam 0.2 mg kg1 and the sedative effects of ketamine plus
midazolam suggest that nefopam is an equal to ketamine plus
midazolam for the prevention of postspinal shivering.
Further studies are needed to conﬁrm this result.
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